rs794727303
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_024529.5(CDC73):c.237+1G>A variant causes a splice donor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_024529.5 splice_donor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Data not reliable, filtered out with message: AC0;AS_VQSR AF: 0.00 AC: 0AN: 1346254Hom.: 0 Cov.: 22 AF XY: 0.00 AC XY: 0AN XY: 676400
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Parathyroid carcinoma Pathogenic:1
This sequence change affects a donor splice site in intron 2 of the CDC73 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CDC73 are known to be pathogenic (PMID: 12434154). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with primary hyperparathyroidism (PMID: 14985403). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 821167). Studies have shown that disruption of this splice site alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 19332451). For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.237+1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide after coding exon 2 of the CDC73 gene. A different substitution at the same nucleotide position, designated as IVS2+1G>C, was identified in several family members affected with primary hyperparathyroidism (Villablanca A et al. J. Med. Genet., 2004 Mar;41:e32). Additionally, functional analyses via minigene assay demonstrated that IVS2+1G>C causes aberrant splicing leading to either exon 2 skipping or retention of four nucleotides at the 5' end of intron 2; both aberrant splicing events were predicted to lead to premature truncation of parafibromin (Hahn MA et al. J. Endocrinol., 2009 Jun;201:387-96). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at